Cargando…
Using health technology assessment to inform insurance reimbursement of high technology medicines in China: an example of cancer immunotherapy
Yingyao Chen and colleagues examine what can be learnt from China’s approach to funding expensive high technology medicines with uncertain long term benefit
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group Ltd.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266439/ https://www.ncbi.nlm.nih.gov/pubmed/37321628 http://dx.doi.org/10.1136/bmj-2022-069963 |
| Sumario: | Yingyao Chen and colleagues examine what can be learnt from China’s approach to funding expensive high technology medicines with uncertain long term benefit |
|---|